VANCOUVER, BC / ACCESSWIRE / January 15, 2020 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY)(OTCQB:BABYF) ('Else Nutrition', 'Else', 'or the 'Company'), a developer of plant-based alternatives to dairy-based infant nutrition, announces today that it has received a formal grant from the Patent & Trademark office in Eurasia and a notice of allowance from the Patent & Trademark office in Japan for the extension of its proprietary, 100% plant-based formulations, to the adult population.
'Both of these are highly encouraging developments as we intend to expand our future product portfolio to address the global adult population,' stated Ms. Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. 'Our 100% plant-based, whole-meal balanced nutrition, has a wide range of functional and meaningful applications for huge consumer markets, well beyond babies and children, as plant-based demand continues to grow world-wide in all segments of the population,' she added.
For more information, contact:
Ms. Chelsie Hodge, Director of Corporate Relations
ELSE Nutrition Holdings Inc.
Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that, to the extent they are not recitations of historical fact, constitute 'forward-looking statements' within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as 'will', 'plan', 'hope to', 'intend' or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the Company's commercialization of its products and expected timing, expected go-to-market strategy (including marketing, proposed markets, sales, customer growth and market position), and industry conditions.
Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct.
Forward-looking statements made in this press release assume, among others, the successful completion of Else's proposed scale-up for its products, and such statements are intended to apply only to the infant formula market for ages 12 months and above, and having all necessary regulatory approval as required by each target market.
Numerous risks and uncertainties could cause the Company's actual results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: consumer demand for the Company's products, whether the Company's current and future products achieve commercialization, uncertainty regarding material changes in laws and regulations, retention of key personnel, the Company's ability to expand into global markets and competitive developments.
The foregoing list of factors is not exhaustive, and other risks and uncertainties not presently known, or believed to be material, to management Additional information and other factors that could affect the operations or financial results of the Company are set out in the Company's Filing Statement dated May 14, 2019 under the heading 'Risk Factors' and may be accessed through the SEDAR website (www.sedar.com).
Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE: ELSE Nutrition Holdings
View source version on accesswire.com: